MEDCHEM 570. First Midterm. January 30, 2015

Similar documents
Metabolism. Objectives. Metabolism. 26 July Chapter 28 1

MEDCHEM 562. First Midterm (KEY) October 15, 2012

Chapter 4. Drug Biotransformation

3. P450 Drug Metabolism DDIs: Induction

Drug Metabolism Phase 2 conjugation reactions. Medicinal chemistry 3 rd stage

Polar bodies are either introduced or unmasked, which results in more polar metabolites Phase I reactions can lead either to activation or

Patrick, An Introduction to Medicinal Chemistry 5e Chapter 11 Pharmacokinetics and related topics

Metabolic Changes of Drugs and Related Organic Compounds. Oxidative Reactions. Shokhan J. Hamid. 3 rd stage/ 1 st course Lecture 6

Chapter 9. Biotransformation

B. Incorrect! Compounds are made more polar, to increase their excretion.

Metabolic Changes of Drugs and Related Organic Compounds

Application of Pharmacogenetics Supplementary Worksheet

Metabolic Changes of Drugs and Related Organic Compounds

It the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues.

METABOLISM. Ali Alhoshani, B.Pharm, Ph.D. Office: 2B 84

Caveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters

Pharmacokinetics of Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

MODULE No.26: Drug Metabolism

MEDCHEM 562. Second Midterm. November 9, 2012

Role of metabolism in Drug-Induced Liver Injury (DILI) Drug Metab Rev. 2007;39(1):

Helping the liver to detoxify mycotoxins

Take-Home Exam Distributed: October 16, 2013, at 1:30 p.m. Due: October 21, 2013, at 10:00 a.m.

Pharmacokinetics Metabolism

The ADME properties of most drugs strongly depends on the ability of the drug to pass through membranes via simple diffusion.

Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics

Pharmacogenetics of Codeine. Lily Mulugeta, Pharm.D Office of Clinical Pharmacology Pediatric Group FDA

Clinical Study Synopsis for Public Disclosure

UNIVERSITY OF GUELPH CHEM 4540 ENZYMOLOGY Winter 2005 Quiz #2: March 24, 2005, 11:30 12:50 Instructor: Prof R. Merrill ANSWERS

Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence

Pharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne

2. List routes of exposure in the order of most rapid response.

3. Describe how variants in the CYP2C19 gene impact Plavix metabolism. 4. Compare molecular genetic technologies for pharmacogenomics testing

Right drug. Right dose. Right now. Delivering on the promise and value of personalized prescribing

Cytokrom P450 (CYP) Hepatic Drug Metabolism. Medicines in plasma. Plasma concentration of a medicine. Eva Brittebo Dept Pharmaceutical Biosciences

BIOPHARMACEUTICS and CLINICAL PHARMACY

EULEXIN PRODUCT INFORMATION NAME OF MEDICINE EULEXIN DESCRIPTION

Toxicant Disposition and Metabolism. Jan Chambers Center for Environmental Health Sciences College of Veterinary Medicine

INTRODUCTION TO PHARMACOKINETICS

PRESCRIBING IN LIVER AND RENAL DISEASE

Welcome to Week Oral Delivery II. Starting week four video. Multiple oral doses video. Calculating Cp for an oral drug

Chem 499. Spring, 2016 Beauchamp. Credit

Mr Ricky Gellissen Imperial College Healthcare NHS Trust, London, UK

Chapter Questions. Modern Pharmacology With Clinical Applications. Sixth Edition

MTnL Tablet/ MTnL Kid Tablet Montelukast & Levocetirizine dihydrochloride

Importance of Multi-P450 Inhibition in Drug Drug Interactions: Evaluation of Incidence, Inhibition Magnitude, and Prediction from in Vitro Data

PRUCAPLA Tablets (Prucalopride)

Current Approaches and Applications of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters

Waters ASMS Users Meeting May 30 th, Overview

Pharmacology med term exam

Using Accelerator Mass Spectrometry to Explain the Pharmacokinetics of Vismodegib Cornelis E.C.A. Hop

There is some evidence to suggest that the half-life of felbamate may be prolonged by gabapentin.

Suspected Isoflurane Induced Hepatitis from Cross Sensitivity in a Post Transplant for Fulminant Hepatitis from Halothane.

Genetics and Genomics: Influence on Individualization of Medication Regimes

BIOMARKERS AND TOXICITY MECHANISMS 07 Mechanisms Metabolism & Detoxification. Luděk Bláha, PřF MU, RECETOX

Lecture 8: Phase 1 Metabolism

Dosage and Administration

Clinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline

Psychotropic Drug Interactions Over the past 2 decades:

BIOCHEMISTRY 460 FIRST HOUR EXAMINATION FORM A (yellow) ANSWER KEY February 11, 2008

Introduction to Pharmacokinetics (PK) Anson K. Abraham, Ph.D. Associate Principal Scientist, PPDM- QP2 Merck & Co. Inc., West Point, PA 5- June- 2017

Pharmacogenetics and Pharmacokinetics

Basic Concepts in Pharmacokinetics. Leon Aarons Manchester Pharmacy School University of Manchester

Farmadol. Paracetamol 10 mg/ml INFUSION SOLUTION

Chem 499. Spring, 2017 Beauchamp. Credit

R 3 NH + + H 2 O R 3 N + H 3 O +

1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?

PHA Final Exam Fall 2001

Infective Liver Disease

Mrs Janet Catt. Pre-Conference Nurse s Course. Royal Free London NHS Foundation Trust. Janet Catt MSc RN Lead Nurse Specialist Practic 12/12/2014

Herbal/Drug Interactions. Gary W. Elmer 11/12/09

Objectives Making CYP450, Drug Interactions, & Pharmacogenetics Easy

AROMASIN 25mg (Tablets)

DEPARTMENT OF PHARMACOLOGY AND THERAPEUTIC UNIVERSITAS SUMATERA UTARA

Levocetirizine dihydrochloride

Click to edit Master title style

INITIATING ORAL AUBAGIO (teriflunomide) THERAPY

Early Life Development of Toxicokinetic Pathways: Framework Case Examples and Implications for Safety Assessment

Deuteration of Drugs for Pharmacokintic Enhancement: Considerations Essential for Success

Rational Dose Prediction. Pharmacology. φαρμακον. What does this mean? pharmakon. Medicine Poison Magic Spell

Elements for a public summary

FDA s Clinical Drug Interaction Studies Guidance (2017 Draft Guidance)

VESIGARD Tablets (Darifenacin hydrobromide)

Montpellier and Nimes University Hospital. 2nd International Workshop on Clinical Pharmacology of Anticancer Drugs Madrid, September the 13th and 14th

METABOLISM/SAFETY CONSIDERATIONS IN DRUG DEVELOPMENT LARRY C WIENKERS DATE

Basic Concepts of TDM

Bassett Healthcare Clinical Laboratory

RSC, February Interplay between enzymes and. clearance and intracellular concentration of drugs. Centre for Applied Pharmacokinetic Research

Title of Lecture: Pharmacokinetics II Metabolism and Excretion (Problem 17, Lecture 2, 2009)

CYTOCHROME P450: Structure-Function

Find this material useful? You can help our team to keep this site up and bring you even more content consider donating via the link on our site.

Principles of Pharmacology. Pharmacokinetics & Pharmacodynamics. Mr. D.Raju, M.pharm, Lecturer PHL-358-PHARMACOLOGY AND THERAPEUTICS-I

Culture Hepatocytes in Human Plasma to Count the free Concentration of Drug in Evaluation of Drug-drug Interaction. Chuang Lu

Effects of Liver Disease on Pharmacokinetics

Composition: Each tablet contain. Levocetirizine. Each 5ml contains. Montelukast. Pharmacokinetic properties:

Valdoxan (agomelatine) in the treatment of Major Depressive Episodes in Adults. Prescriber Guide Information for Healthcare Professionals

BASIC PHARMACOKINETICS

Mechanistic Toxicology

HUMAN BIOTRANSFORMATION. ANDREW PARKINSON, BRIAN W. OGILVIE, BRANDY L. PARIS, TIFFINI N. HENSLEY, and GREG J. LOEWEN XenoTech LLC, Lenexa, KS

Liver Function Tests

Pharmacokinetics in the critically ill. Intensive Care Training Program Radboud University Medical Centre Nijmegen

Transcription:

Name MEDCHEM 570 First Midterm January 30, 2015 Instructions: Exam packet totals 7 pages. The last page has a 5 points extra credit question. If you need additional space for a question go to the back of that page and tell me you did so. Write legibly and in complete sentences when indicated. Read the questions carefully and answer the questions you know first. 1

1. (20 points) True False (circle the correct answer)-2 points each T F The jejunum is more acidic than the duodenum. T F Glucuronyl transferases are cytosolic enzymes. T F Bioactivation of prodrug Plavix (clopidogrel) requires CYP1A2. T F CYP2D6 IM status is important for warfarin dosing. T F Ritonavir is commonly used for PI boosting. T F Mitochondria contain P450 enzymes but they are not important in drug metabolism. T F Phase II sulfate conjugates are not charged above ph 10. T F Esterases are Phase II enzymes. T F Induction of CYP2E1 limits the toxicity of acetaminophen. T F CYP2D6 PM s have low debrisoquine metabolic ratios. 2) (20 points) Provide short definitions including one major item of relevance for drug metabolism (2-3 sentences total) of the following terms (structures/diagrams are welcome). Answer 4 of 5; cross out the one you don t want graded. 5 points each. If you didn t indicate which one you didn t want answered and you gave an answer to all five, the first four were graded. a) Microsomes Microsomes are donut-shaped vesicles made by homogenizing (lysing and shearing the ER) liver cells and centrifuging at 10k x g and 100k x g. The pellet after the second centrifugation contains the microsomes and is re-suspended. These preparations contain P450 enzymes and glucuronyl transferases, and are used to study drug metabolism in vitro. b) Carbamazepine Carbamazepine is an anti-epileptic drug which is metabolized by and induces CYP3A4. It is important in polytherapy involving other CYP3A4 substrates such as oral contraceptives as it causes increased clearance of these other drugs. Additionally, carbamazepine forms as stable arene oxide upon P450-mediated oxidation. c) Halothane Halothane is an inhaled anesthetic. It is no longer used in the US, but is still widely used in developing countries. It is bioactivated by CYP2E1 into a toxic metabolite that is believed to react with Lys residues. Halothane hepatitis is seen after repeated use and is thought to be an immune-mediated response. d) Carboxylesterases Phase I drug metabolizing enzymes that cleave ester bonds to form an alcohol and a carboxylic acid. They are particularly important in the bioactivation of pro-drugs into their active forms. Some examples of drugs that require carboxylesterase activity are Tamiflu, Fluphenazine esters and Enalapril. 2

e) Arene Oxide An arene oxide is an unstable, reactive, and highly electrophilic intermediate formed during P450-mediated oxidation of aromatic rings. They often undergo an NIH shift to form phenols. They can adduct DNA and cause cell damage. 3) (12 points) The Black Box Warning on the label of the anti-androgen flutamide states that serum transaminase levels should be measured before and during therapy. a) Give an example of a transaminase and explain why we measure serum transaminase levels in this case. 3 points ALT or AST ALT and AST are liver enzymes and are released into the bloodstream upon liver damage, thus elevated levels in the blood indicate liver damage. b) Provide the names of two other types of common clinical tests that are often employed and describe briefly why they are also good markers for this type of problem. 6 points BIL bilirubin is processed in the liver and then excreted in the urine. Elevated bilirubin indicates an inability of the liver to perform this function. PT/INR the liver is responsible for releasing clotting factors into the blood stream. Liver damage impairs this function and clotting factor levels go down. This results in a longer clotting time and increased INR. Either AST or ALT was also accepted (whichever one was not mentioned in part 3a) c) Pharmacists can alert patients to signs and symptoms of a developing problem with this drug. Name two. 3 points Any two of nausea, vomiting, abdominal pain, fatigue, anorexia, flu-like symptoms, hyperbilirubinuria, jaundice, upper right quadrant tenderness. 4) (15 points) The magnitude of a particular inhibitory drug-drug interaction depends upon a number of factors that relate to the metabolism and pharmacokinetics the object drug. In some cases the site of administration of the object drug is a major factor. Consider the physiology of blood circulation and answer the following. 5 points each. Scenario for a) and b): A given interactant drug increases the AUC of an iv dose of midazolam by 3-fold. a) What dose adjustment would be required to manage this interaction. What basic PK equation do you use in this analysis. You would LOWER the dose by 3-fold (to 1/3 the original dose). The equation is CL = D/AUC. Variations of that equation were accepted as well; AUC = D/CL, AUC*CL=D, etc. 3

b) Would the magnitude of effect on AUC for an oral dose be equal to, greater than, or less than that of the iv dose. Explain your reasoning in a couple of sentences (no equations please). The magnitude of effect on AUC for an oral dose would be GREATER than or EQUAL to the magnitude of effect on AUC for an IV dose. This is because of the first pass effect on an oral dose, specifically the inhibition of enzymes in the enterocytes, which would affect the oral dose but not the IV dose since the intestines and liver are in series for oral drugs. c) Hypothesis: For the detection of the effect of a new drug candidate on CYP1A2 activity in vivo, caffeine is a better object drug than theophylline or clozapine. Explain why this is true (ignore the pharmacological effects of these potential object drugs). An equation would be useful but not required. Caffeine is 90 % metabolized by CYP1A2 whereas theophylline and clozapine are only ~60 % metabolized by CYP1A2. This makes caffeine plasma levels more sensitive to CYP1A2 inhibition and/or induction, thus making it a better object drug than either theophylline or clozapine. 5) (9 points) What evolutionary advantages are conferred by the following facts related to the metabolism of xenobiotics (one or two sentences each). 3 points each a) A P450 enzyme usually will produce multiple metabolites of a given substrate. Producing multiple metabolites prevents any one metabolite concentration from being too high. In cases were toxic metabolites are involved, the final concentration of that metabolite would be lower in cases where other metabolites were also formed than if the toxic metabolite was the only one being made. b) Multiple P450 enzymes will oxidize a given xenobiotic. Having multiple enzymes able to clear a given drug protects against any inter-individual variability as well as inhibition of any given enzyme responsible for clearance. If an individual were deficient for an enzyme needed for the clearance of a drug due to a polymorphism, for example, or were taking another drug that inhibited that enzyme, other routes of clearance of the drug are available. c) The blood from the intestines is directed to the liver. This ensures that anything absorbed into the body through the intestines goes through first-pass metabolism. Any toxins, therefore, have a chance of being cleared before reaching systemic circulation. 6) (24 points) Atomoxetine is an amphetamine analog that is used in the treatment of ADHD (attention deficit hyperactivity disorder). Normally, in pediatric populations, the dose of this drug is determined via individualized dose escalation to desired effect using an algorithm that monitors therapeutic and toxic effects of the drug. The pharmacokinetics of atomoxetine are largely controlled by CYP2D6. Sites of metabolism by CYP2D6 are indicated by the arrows shown below (aromatic hydroxylation, N-dealkylation and O-dealkylation). 4 points each 4

Note that partial structures using R groups are OK in your answers. c. (trace) b. (minor) CH 3 O N CH3 Atomoxetine a. (major) a) For metabolite a. show the structure of the unstable intermediate and final metabolic product. Intermediate Product b) Metabolite a is found in urine however the dominant metabolite in urine is the product of a Phase II enzyme that produces a further metabolite and that uses the cofactor shown below. Show the structure of this urinary metabolite, name the enzyme involved and the cofactor shown. Explain why (chemical reason) this type of secondary metabolite would be expected to be found in urine. The cofactor is UDPGA and the enzyme is glucuronyl transferase or GT or UGT. It s expected to be excreted into the urine because it s polar and charged 5

c) For metabolite b. show the structure and name the unstable intermediate. Also show the structure of the final metabolic product. Would you expect this metabolite to accumulate in vivo? Why or why not? OH R N H R NH 2 Carbinolamine Hemi-aminal The metabolite would be expected to accumulate because it is not more or less polar than the parent (which accumulates). d) For metabolite c. show the structure of the unstable intermediate and both final metabolic products. Intermediate Products In a very large study of dosing of atomoxetine (roughly 1100 EMs and 100 PMs) prescribers dosed pediatric patients to optimal effect using standard protocols without foreknowledge of metabolizer status and the results of blood concentration measurements. Note that the final mean doses for EMs and PMs (week 10)were not significantly different. The plasma levels are shown below (left). Average AUC for the EMs and PMs were 4 ug*hr/ml and 28 ug*hr/ml respectively. asma atomoxetine exposures in CYP2D6 extensive and poor metabolizers by week on e) Based on the dose and AUC information only estimate the fraction of atomoxetine that is cleared by CYP2D6 and explain your reasoning. f!!! =!"#$!!"#$ è = 6/7 = 85% of atomoxetine is cleared by CYP2D6!"#$ 6

f) From the left graph it appears that the time to steady state in the PMs was longer than for the EMs. Why would you expect this to be true? From the graph, we see that PMs have higher AUCs. This would mean that the clearance of atomoxetine is lower and that the half-life of atomoxetine in PMs is higher. Drugs with a higher t 1/2 take longer to reach steady state. g) (5 points extra credit) The conclusion of the study was that foreknowledge of metabolizer status is not required in the dosing of atomoxetine. Consider this conclusion which is fully supported by the data. Does it make sense to you? Why or why not? Hint: Focus on the plasma concentration-effect vs. dose-effect relationships for this drug in your answer. Suggest one plausible reason that might explain these results. Recall from above: prescribers dosed pediatric patients to optimal effect using standard protocols without foreknowledge of metabolizer status and the results of blood concentration measurements and note that the final dose they arrived at for EMs and PMs was the same. Finally the blood levels were 8 fold higher in the PMs. Clearly they dosed to an expected final dose, not effect which confounded the study. A wide therapeutic index for atemoxetine would potentially be a factor. Either that or for some unexplained reason CYP2D6 PM s are more resistant to the effect of the drug. 7